Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -27.15% | -36.24% | -43.89% | -32.79% | -19.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -27.15% | -36.24% | -43.89% | -32.79% | -19.56% |
| Cost of Revenue | -- | -- | -- | -73.40% | -67.33% |
| Gross Profit | -12.69% | -14.54% | -18.47% | -13.50% | 13.33% |
| SG&A Expenses | -31.03% | -28.64% | -10.52% | -3.01% | -2.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.47% | -20.60% | -18.54% | -13.13% | -6.22% |
| Operating Income | 6.10% | 10.85% | -0.66% | -0.34% | -2.98% |
| Income Before Tax | -28.05% | -18.79% | -37.76% | 28.01% | 30.76% |
| Income Tax Expenses | 116.58% | 17.11% | 42.26% | -4,655.56% | -388.61% |
| Earnings from Continuing Operations | -28.51% | -18.83% | -37.92% | 28.26% | 30.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.51% | -18.83% | -37.92% | 28.26% | 30.95% |
| EBIT | 6.10% | 10.85% | -0.66% | -0.34% | -2.98% |
| EBITDA | 5.26% | 9.30% | -3.36% | -3.85% | -6.59% |
| EPS Basic | 23.09% | 11.52% | -17.06% | 36.88% | 35.55% |
| Normalized Basic EPS | 45.86% | 30.06% | 7.13% | 1.87% | -4.66% |
| EPS Diluted | 23.18% | 11.61% | -16.94% | 36.80% | 35.48% |
| Normalized Diluted EPS | 45.67% | 29.80% | 6.77% | 2.25% | -4.28% |
| Average Basic Shares Outstanding | 73.02% | 39.61% | 22.90% | 13.98% | 7.16% |
| Average Diluted Shares Outstanding | 72.23% | 38.97% | 22.33% | 14.46% | 7.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |